NYSE:NVO - アナリストの将来予測と過去の財務データ ( )DKK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	406,381	149,387	118,162	163,905	22
12/31/2025	349,334	127,974	94,213	140,958	26
12/31/2024	290,128	101,959	74,396	122,755	26
6/30/2024	258,003	89,898	66,027	115,334	N/A
3/31/2024	244,243	89,276	50,304	93,408	N/A
12/31/2023	232,261	83,683	70,012	108,908	N/A
9/30/2023	214,490	75,312	77,825	106,458	N/A
6/30/2023	201,325	67,239	67,497	89,731	N/A
3/31/2023	188,290	61,129	67,341	85,115	N/A
12/31/2022	176,954	55,525	64,134	78,887	N/A
9/30/2022	167,195	52,825	57,875	68,769	N/A
6/30/2022	157,251	50,539	57,680	66,037	N/A
3/31/2022	149,027	49,344	59,665	67,331	N/A
12/31/2021	140,800	47,757	47,615	55,000	N/A
9/30/2021	134,605	46,183	40,213	58,189	N/A
6/30/2021	129,910	44,362	31,814	54,188	N/A
3/31/2021	126,875	42,864	31,337	53,194	N/A
12/31/2020	126,946	42,138	29,870	51,951	N/A
9/30/2020	127,225	41,537	44,800	56,944	N/A
6/30/2020	126,575	41,433	47,621	56,126	N/A
3/31/2020	126,605	40,403	36,987	46,904	N/A
12/31/2019	122,021	38,951	35,551	46,782	N/A
9/30/2019	119,336	38,731	36,785	49,029	N/A
6/30/2019	116,821	37,574	31,251	43,960	N/A
3/31/2019	114,192	38,322	32,202	44,691	N/A
12/31/2018	111,831	38,628	32,206	44,616	N/A
9/30/2018	110,091	38,384	31,576	43,236	N/A
6/30/2018	108,943	39,117	33,787	44,538	N/A
3/31/2018	110,174	38,725	N/A	38,885	N/A
12/31/2017	111,696	38,130	N/A	41,168	N/A
9/30/2017	113,276	38,576	N/A	46,289	N/A
6/30/2017	114,199	38,609	N/A	48,557	N/A
3/31/2017	113,020	38,626	N/A	52,937	N/A
12/31/2016	111,780	37,925	N/A	48,314	N/A
9/30/2016	111,084	37,484	N/A	47,280	N/A
6/30/2016	110,339	36,064	N/A	44,179	N/A
3/31/2016	109,939	34,439	N/A	41,656	N/A
12/31/2015	107,927	34,860	N/A	38,287	N/A
9/30/2015	103,636	33,131	N/A	35,469	N/A
6/30/2015	99,093	31,248	N/A	35,578	N/A
3/31/2015	93,663	29,899	N/A	31,729	N/A
12/31/2014	88,806	26,481	N/A	31,692	N/A
9/30/2014	85,919	26,005	N/A	29,763	N/A
6/30/2014	84,181	25,920	N/A	23,783	N/A
3/31/2014	83,932	25,660	N/A	22,941	N/A
12/31/2013	83,572	25,184	N/A	25,942	N/A
9/30/2013	82,836	24,886	N/A	22,084	N/A

アナリストによる今後の成長予測

収入対貯蓄率: NVOの予測収益成長率 (年間14.4% ) は貯蓄率 ( 2.5% ) を上回っています。

収益対市場: NVOの収益 ( 14.4% ) US市場 ( 15.2% ) よりも低い成長が予測されています。

高成長収益: NVOの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: NVOの収益 ( 13.3% ) US市場 ( 8.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: NVOの収益 ( 13.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: NVOの自己資本利益率は、3年後には非常に高くなると予測されています ( 65 %)。

Novo Nordisk 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Novo Nordisk A/S Provides Earnings Guidance for the Year 2024

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Recent updates

Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation

Novo Nordisk A/S Decides to Pay Interim Dividend for 2024, Payable on 19 August 2024 for A and B Shares and 26 August 2024 for ADRs

Novo Nordisk: Growth Only Limited By Manufacturing Capacity

Novo Nordisk A/S Provides Earnings Guidance for the Year 2024

Novo Nordisk: Better Buying Opportunities Ahead

European Regulatory Authority Adopts A Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events

Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec

Novo Nordisk: Buy On Dips

Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy

Novo Nordisk: Leading The Fight Against Diabetes And Obesity

Novo Nordisk: Considerable Growth Beyond Ozempic

The FTC Cracks Down On Novo Nordisk's Ozempic

Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada

Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy

Novo Nordisk: The Moat Won't Last Forever

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified

Novo Nordisk, A Very Healthy Pharma Stalwart

Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy

Novo Nordisk: Irrational Exuberance Isn't Worth The Risk

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk: Outlook For Weight Loss Drugs In 2024

Taking Novo Nordisk To The Next Level

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly

Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity

Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

Novo Nordisk: Catching The Falling Knife Now Could Really Hurt

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Novo Nordisk: Strong Fundamentals Meet Technical Uptrends

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Novo Nordisk: Denmark's Coca-Cola

The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier

Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘